Payment overview · 2025
General Payments
$664.84
31 reported records · 12 companies
Healthcare provider profile · identity verified
Robert L Giffin, MD
Allopathic & Osteopathic Physicians|Family Medicine · VICKSBURG, MS · NPI 1376584052
Verified facts
What the public records show
CMS Open Payments records show Robert L Giffin, MD received $664.84 in general payments during 2025 across 31 reported records.
Astellas Pharma US Inc accounted for 34.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $228.85 | 34.4% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $117.49 | 17.7% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $81.12 | 12.2% | 5 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $42.27 | 6.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.41 | 6.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.61 | 4.6% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $27.67 | 4.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.77 | 3.7% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $22.56 | 3.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.70 | 2.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.57 | 2.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.82 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $664.84 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $228.85 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $117.49 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $65.91 | 4 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $42.27 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $41.41 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.61 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.61 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $27.67 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $27.67 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.77 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $22.56 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
81 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
106 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
106 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
97 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 760 | 162 |
| Atorvastatin Calcium | Atorvastatin Calcium | 707 | 157 |
| Levothyroxine Sodium | Levothyroxine Sodium | 515 | 99 |
| Metformin Hcl | Metformin Hcl | 436 | 89 |
| Omeprazole | Omeprazole | 324 | 68 |
| Lisinopril | Lisinopril | 283 | 64 |
| Furosemide | Furosemide | 280 | 68 |
| Gabapentin | Gabapentin | 276 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 275 | 61 |
| Simvastatin | Simvastatin | 268 | 56 |
| Glimepiride | Glimepiride | 249 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 230 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 223 | 59 |
| Alprazolam | Alprazolam | 221 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 215 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 211 | 51 |
| Potassium Chloride | Potassium Chloride | 206 | 55 |
| Meloxicam | Meloxicam | 199 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 197 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 191 | 40 |
| Trazodone Hcl | Trazodone Hcl | 189 | 25 |
| Losartan Potassium | Losartan Potassium | 183 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 166 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 154 | 35 |
| Sertraline Hcl | Sertraline Hcl | 149 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 140 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 130 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 125 | 27 |
| Terazosin Hcl | Terazosin Hcl | 123 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 116 | 29 |
| Famotidine | Famotidine | 111 | 27 |
| Jardiance | Empagliflozin | 106 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 24 |
| Eliquis | Apixaban | 97 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 91 | 27 |
| Diclofenac Sodium | Diclofenac Sodium | 90 | 22 |
| Ibandronate Sodium | Ibandronate Sodium | 83 | 18 |
| Farxiga | Dapagliflozin Propanediol | 81 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 75 | 15 |
| Atenolol | Atenolol | 75 | 20 |
| Tramadol Hcl | Tramadol Hcl | 74 | 18 |
| Estradiol | Estradiol | 73 | 14 |
| Allopurinol | Allopurinol | 70 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | suppressed |
| Ozempic | Semaglutide | 67 | suppressed |
| Ezetimibe | Ezetimibe | 65 | 17 |
| Ramipril | Ramipril | 65 | 16 |
| Celecoxib | Celecoxib | 64 | 15 |
| Lorazepam | Lorazepam | 63 | 14 |
| Diazepam | Diazepam | 62 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 61 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 59 | 15 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 57 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 36 |
| Montelukast Sodium | Montelukast Sodium | 57 | 13 |
| Pregabalin | Pregabalin | 57 | suppressed |
| Cephalexin | Cephalexin | 56 | 47 |
| Clonidine Hcl | Clonidine Hcl | 55 | 13 |
| Donepezil Hcl | Donepezil Hcl | 55 | 12 |
| Memantine Hcl | Memantine Hcl | 55 | 12 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Levetiracetam | Levetiracetam | 53 | suppressed |
| Bupropion Xl | Bupropion Hcl | 52 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 11 |
| Divalproex Sodium | Divalproex Sodium | 51 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 16 |
| Nifedipine Er | Nifedipine | 49 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | suppressed |
| Carvedilol | Carvedilol | 48 | 13 |
| Doxepin Hcl | Doxepin Hcl | 47 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 46 | suppressed |
| Fenofibrate | Fenofibrate | 46 | 11 |
| Lansoprazole | Lansoprazole | 46 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Temazepam | Temazepam | 45 | suppressed |
| Aripiprazole | Aripiprazole | 44 | suppressed |
| Chlorthalidone | Chlorthalidone | 44 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 44 | suppressed |
| Ibuprofen | Ibuprofen | 44 | 12 |
| Januvia | Sitagliptin Phosphate | 44 | suppressed |
| Fluconazole | Fluconazole | 43 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Prednisone | Prednisone | 41 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Azithromycin | Azithromycin | 38 | 33 |
| Meclizine Hcl | Meclizine Hcl | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 37 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Digoxin | Digoxin | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 22 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 26 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Glyburide | Glyburide | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 25 |
| Cefdinir | Cefdinir | 28 | 25 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Nystatin | Nystatin | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 14 |
| Amoxicillin | Amoxicillin | 25 | 14 |
| Baclofen | Baclofen | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 23 | suppressed |
| Carbamazepine | Carbamazepine | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Mupirocin | Mupirocin | 13 | 11 |
| Risperidone | Risperidone | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Glucagon Emergency Kit | Glucagon Hcl | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $664.84 · 31 records | Astellas Pharma US Inc | ABRYSVO, BREZTRI, CLOTTRIEVER BOLD CATHETER, COMIRNATY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, INSPIRE, MOUNJARO, PREVNAR 20, QULIPTA, UBRELVY, VOQUEZNA, Veozah, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error